MarketPulse
B

$BCRX

5 articles found
4 positive
0 negative
1 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Biocryst Pharmaceuticals, Inc.

BioCryst Lands $70M Deal, Reports ORLADEYO Growth Ahead of Navenibart Catalyst

BioCryst posts 11% ORLADEYO revenue growth to $148.3M in Q1 2026, inks $70M European licensing deal for navenibart with up to $275M in milestones.
BCRXrevenue growthclinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Na

BioCryst Lands $70M European Deal for Hereditary Angioedema Drug

BioCryst secures $70M upfront plus $275M milestone payments for navenibart European rights, reinforcing strategy to focus on U.S. commercialization.
BCRXPhase 3 clinical trialORLADEYO
GlobeNewswire Inc.GlobeNewswire Inc.··Biocryst Pharmaceuticals, Inc.

BioCryst Names Pharma Veteran Menon as Chief R&D Officer Amid Pipeline Expansion

BioCryst appoints experienced pharma executive Sandeep Menon as Chief R&D Officer, bolstering leadership as it advances navenibart toward FDA approval.
BCRXFDA approvalclinical development
BenzingaBenzinga··Globe Newswire

BioCryst Grants 65,850 RSUs to New Hires Under Nasdaq Inducement Rule

BioCryst awards 65,850 RSUs to six new employees under Nasdaq inducement rule, vesting over four years starting March 2027.
BCRXrestricted stock unitsbiotechnology
GlobeNewswire Inc.GlobeNewswire Inc.··Na

BioCryst Achieves Historic Profitability as ORLADEYO Revenue Surges 38%

BioCryst achieved historic profitability with ORLADEYO revenue surging 38% to $601.8 million. FDA approval for pediatric formulation and Astria acquisition expand HAE treatment portfolio.
BCRXFDA approvalprofitability